Yinjia Bio and Chengkong Shuxin Forge Strategic Partnership to Advance AI-Driven, Automated High-Throughput Dry-Wet Closed-Loop Protein Synthesis

Recently, YINJIA BIOSCIENCES and Hangzhou Chengkong Shuxin Biotechnology Co., Ltd. ("Chengkong Shuxin") officially signed a strategic cooperation agreement in Shanghai.

China's "15th Five-Year Plan" has clearly identified biomanufacturing as a core track for future industries. One of the key development goals is to promote the deep integration of "AI + biomanufacturing," achieving accelerated breakthroughs in core areas such as gene function analysis, intelligent design of proteins and metabolic pathways, reducing the R&D cycle from "years" to "months" or even "days."

As an innovative technology platform company driven by AI, YINJIA BIOSCIENCES focuses on the wide application of high-end proteins in biomedicine and other major livelihood fields. With years of deep cultivation in its core business, YINJIA BIOSCIENCES has made breakthrough progress in AI-assisted protein design, cell-free protein synthesis, and expression validation. Using generative AI technology, researchers can generate novel protein sequences and structures from scratch without relying on traditional natural protein templates, achieving an unprecedented improvement in the efficiency and capability of protein design. The company’s pride lies in its cell-free protein synthesis technology, which completely bypasses the time-consuming processes of cell cloning, transformation, and culturing that typically take several days. Instead, it directly achieves rapid, on-demand synthesis of functional proteins from DNA templates in vitro. Moreover, the reaction system is entirely open, allowing for the easy addition of non-natural amino acids, fluorescent probes, or detection substrates, enabling seamless integration of synthesis and characterization.

YINJIA BIOSCIENCES' self-developed first-generation CFPS E.coli cell-free protein expression system enables the rapid synthesis of various functional proteins from DNA to those with molecular weights over 100 Kd in vitro, featuring an open reaction system compatible with multiple detection substrates.

Today, AI has been able to significantly improve the efficiency of biotech R&D. However, the results of algorithms still need to be validated in the physical world, and high-throughput, digital, and traceable biological experiments have become a bottleneck constraining AI-driven biotech R&D. Based on next-generation digital microfluidic chip technology, Chengkong Shuxin has pioneered a programmable AI "lab-on-a-chip" – the Turing Universal Intelligent Biological Workstation. Within a biochip the size of a mobile phone screen, it achieves high-throughput and flexible control of microdroplets (nanoliter to microliter scale) entirely through software, addressing the challenges faced by traditional wet lab experiments that rely on manual operations, high costs, low efficiency, and the inability to form a true digital closed loop.